Stifel initiated coverage on Compass Pathways plc, saying, “The Time Is Now for Psychedelics.
Compass is a clinical-stage biotechnology company focused on developing psychedelics-based drugs for neuropsychiatric disorders.
The analyst equates COMP360 to Spravato 2.0. Johnson & Johnson’s Spravato (esketamine) is a nasal spray for TRD and major depressive disorder (MDD), selling over ~$1 billion annually.